Saccharide analog, 2‐deoxy‐d‐glucose enhances 4‐1BB‐mediated antitumor immunity via PD‐L1 deglycosylation

Triple‐negative breast cancer (TNBC) lacks a well‐defined molecular target and is associated with poorer outcomes compared to other breast cancer subtypes. Programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) blockade therapy shows a 10% to 20% response rate in TNBC patients. Our previous studies show that PD‐L1 proteins are heavily glycosylated in TNBC, and the glycosylation plays an important role in the PD‐L1 protein's...